Enanta Pharmaceuticals, Inc.
ENTA
$11.35
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.98M | -71.54M | -81.89M | -92.01M | -96.42M |
| Total Depreciation and Amortization | 4.93M | 4.93M | 4.59M | 3.78M | 3.17M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.46M | 15.53M | 18.12M | 21.36M | 23.70M |
| Change in Net Operating Assets | 34.76M | 36.91M | 39.91M | 43.69M | 14.08M |
| Cash from Operations | -7.84M | -14.17M | -19.27M | -23.18M | -55.46M |
| Capital Expenditure | -1.77M | -4.29M | -12.90M | -20.39M | -26.78M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -57.77M | -71.56M | 53.24M | 77.51M | 104.04M |
| Cash from Investing | -59.54M | -75.85M | 40.35M | 57.12M | 77.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 74.99M | 74.94M | 145.00K | 162.00K | 190.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -32.90M | -32.44M | -26.76M | -25.67M | -25.93M |
| Cash from Financing | 42.10M | 42.50M | -26.62M | -25.51M | -25.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.29M | -47.52M | -5.54M | 8.43M | -3.94M |